431 related articles for article (PubMed ID: 16418394)
1. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
Peng G; Lei KJ; Jin W; Greenwell-Wild T; Wahl SM
J Exp Med; 2006 Jan; 203(1):41-6. PubMed ID: 16418394
[TBL] [Abstract][Full Text] [Related]
2. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.
Chen K; Huang J; Zhang C; Huang S; Nunnari G; Wang FX; Tong X; Gao L; Nikisher K; Zhang H
J Virol; 2006 Aug; 80(15):7645-57. PubMed ID: 16840343
[TBL] [Abstract][Full Text] [Related]
3. Protecting APOBEC3G: a potential new target for HIV drug discovery.
Stopak K; Greene WC
Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
[TBL] [Abstract][Full Text] [Related]
4. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3G targets human T-cell leukemia virus type 1.
Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
[TBL] [Abstract][Full Text] [Related]
6. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
7. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Sheehy AM; Gaddis NC; Malim MH
Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
[TBL] [Abstract][Full Text] [Related]
8. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K; de Noronha C; Yonemoto W; Greene WC
Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
[TBL] [Abstract][Full Text] [Related]
10. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.
Kremer M; Schnierle BS
Curr HIV Res; 2005 Oct; 3(4):339-44. PubMed ID: 16250885
[TBL] [Abstract][Full Text] [Related]
12. [The innate antiretroviral defense of human cells, based on the DNA editing].
Pupecka M; Pacak A
Postepy Biochem; 2006; 52(3):247-52. PubMed ID: 17201059
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
14. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.
Jost S; Turelli P; Mangeat B; Protzer U; Trono D
J Virol; 2007 Oct; 81(19):10588-96. PubMed ID: 17652382
[TBL] [Abstract][Full Text] [Related]
15. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA.
Yang B; Chen K; Zhang C; Huang S; Zhang H
J Biol Chem; 2007 Apr; 282(16):11667-75. PubMed ID: 17272283
[TBL] [Abstract][Full Text] [Related]
16. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
17. Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.
Tanaka Y; Marusawa H; Seno H; Matsumoto Y; Ueda Y; Kodama Y; Endo Y; Yamauchi J; Matsumoto T; Takaori-Kondo A; Ikai I; Chiba T
Biochem Biophys Res Commun; 2006 Mar; 341(2):314-9. PubMed ID: 16426578
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
Goncalves J; Santa-Marta M
Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
[TBL] [Abstract][Full Text] [Related]
19. Multifaceted antiviral actions of APOBEC3 cytidine deaminases.
Chiu YL; Greene WC
Trends Immunol; 2006 Jun; 27(6):291-7. PubMed ID: 16678488
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.
Shirakawa K; Takaori-Kondo A; Kobayashi M; Tomonaga M; Izumi T; Fukunaga K; Sasada A; Abudu A; Miyauchi Y; Akari H; Iwai K; Uchiyama T
Virology; 2006 Jan; 344(2):263-6. PubMed ID: 16303161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
